"We are going to need investors or partners." In order to lay the foundations for this, the researchers founded the spin off company Priavoid Gmb H out of Research Centre Jülich and HHU Düsseldorf in September 2017.About Priavoid: Priavoid was founded in September 2017 as a spin-off of the Jülich Research Center and the Heinrich Heine University Düsseldorf in Germany.The study will evaluate the safety and tolerability of the oral dosage form of PRI-002 in healthy volunteers. Dieter Willbold, developer of PRI-002 and director of the Jülich Institute of Structural Biochemistry, was present in Vienna while the Phase I study started."We and our partners worked hard to prepare the study in the most careful and best possible way," says Dieter Willbold.
There is hardly a better example of this than the new therapeutic perspective against Alzheimer's disease".
Oral application of PRI-002 in mice with Alzheimer-like symptoms has reliably yielded significant cognitive improvements.
Now the positive results for safety and tolerability from preclinical studies need to be confirmed in humans.
The company is developing drugs comprised exclusively of D-enantiomeric peptides (all-D-peptides) to combat neurodegenerative diseases like Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Huntington´s disease Parkinson´s disease and different tauopathies. Dieter Willbold on Privivoid harma Ventures (Nov 2017) Institute of Complex Systems Structural Biochemistry (ICS-6) Press Releases: Phase I Clinical Trials Approved for Alzheimer’s Drug Candidate (Press Release, 20 March 2018) Entrepreneurs Develop Drugs Against Alzheimer’s (Press Release, 22 September 2017) Prof.
The most advanced compound is PRI-002, a drug candidate for the causal treatment of Alzheimer’s disease, which is now being tested in a Phase I Clinical Trial. Dieter Willbold Institute of Complex Systems (ICS-6), Forschungszentrum Jülich Tel.